{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:57:05Z","timestamp":1777859825152,"version":"3.51.4"},"reference-count":9,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Objectives: To investigate the perception of community pharmacists on the down-scheduling of 5-HT3 antagonists to pharmacist-only-medicine for treatment of acute nausea and\/or vomiting in Australia. Methods: A nationwide anonymous survey targeting Australian community pharmacists was conducted from April to May 2023. Responses were collected and analysed quantitively or qualitatively, where appropriate. Key findings: Participants reported that 5-HT3 antagonists were effective at treating nausea and\/or vomiting and would likely recommend their use. Training is required to manage supply due to concerns related to their side effects. Conclusion: Participants supported down-scheduling of 5-HT3 antagonists for the treatment of nausea and\/or vomiting in Australia. A pilot study on the provision of 5-HT3 antagonists by pharmacists is recommended as is the development of guidelines for pharmacist-only supply before down-scheduling is considered.<\/jats:p>","DOI":"10.1177\/08971900241236379","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T06:06:31Z","timestamp":1708495591000},"page":"1044-1047","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding Australian Pharmacists\u2019 Perceptions on the Utilisation of Oral 5-HT3 Antagonists as Pharmacist-Only Anti-Emetics in Comparison to Oral D2 Antagonists"],"prefix":"10.1177","volume":"37","author":[{"given":"Aiden","family":"Hendry","sequence":"first","affiliation":[{"name":"Clinical and Health Sciences, University of South Australia, Adelaide, AU-SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Janetzki","sequence":"additional","affiliation":[{"name":"Clinical and Health Sciences, University of South Australia, Adelaide, AU-SA, Australia"},{"name":"Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, AU-SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8184-4341","authenticated-orcid":false,"given":"Wern Chern","family":"Chai","sequence":"additional","affiliation":[{"name":"Clinical and Health Sciences, University of South Australia, Adelaide, AU-SA, Australia"},{"name":"Health and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, AU-SA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"7","key":"bibr1-08971900241236379","first-page":"28","volume":"78","author":"Bouwer A","year":"2011","journal-title":"S Afr Pharmaceut J"},{"key":"bibr2-08971900241236379","volume-title":"The Poisons Standard (The SUSMP)","author":"Therapeutic Goods Administration","year":"2023"},{"key":"bibr3-08971900241236379","volume-title":"Pharmaceutical Benefits Scheme: Ondansetron","author":"Pharmaceutical Benefits Scheme","year":"2023"},{"key":"bibr4-08971900241236379","volume-title":"1.2 Ondansetron, Therapeutic Goods Administration","author":"Therapeutic Goods Administration","year":"2020"},{"key":"bibr5-08971900241236379","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211029702"},{"issue":"10","key":"bibr6-08971900241236379","first-page":"CD012859","volume":"10","author":"Weibel S","year":"2020","journal-title":"Cochrane Database of Systemic Reviews"},{"key":"bibr7-08971900241236379","first-page":"103248","volume":"74","author":"Sheikh Hassan M","year":"2022","journal-title":"Annals of Medicines and Surgery"},{"key":"bibr8-08971900241236379","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5329"},{"key":"bibr9-08971900241236379","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2013.10.026"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241236379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900241236379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900241236379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:38:26Z","timestamp":1777509506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900241236379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/08971900241236379"],"URL":"https:\/\/doi.org\/10.1177\/08971900241236379","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}